Combination Therapy Stroke Trial: recombinant tissue-type plasminogen activator with/without lubeluzole.
D000203:Activities of Daily Living; D000368:Aged; D002543:Cerebral Hemorrhage / Q000139:chemically induced; D004311:Double-Blind Method; D005240:Feasibility Studies; D005260:Female; D015600:Glasgow Coma Scale; D006801:Humans; D008297:Male; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D010960:Plasminogen Activators / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D020521:Stroke / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use*; D010959:Tissue Plasminogen Activator / Q000009:adverse effects / Q000627:therapeutic use*